ArticleEye (London, England)2024
Evaluation of OCT biomarker changes in treatment-naive neovascular AMD using a deep semantic segmentation algorithm.
Article in Eye (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Review
- Practical Challenges for the Implementation of AI-Based Image Analysis in Ophthalmology Research: Insights and Recommendations from a Swiss Multicentric Study.Klinische Monatsblatter fur Augenheilkunde · 2026Article
- Advancing personalised therapy in neovascular AMD through deep learning-based OCT biomarker quantification.Eye (London, England) · 2026Article
- Efficacy and Safety of Intravitreal Faricimab in Age-Related Macular Degeneration-A Review.Journal of clinical medicine · 2025Review
- AI-Based Response Classification After Anti-VEGF Loading in Neovascular Age-Related Macular Degeneration.Diagnostics (Basel, Switzerland) · 2025Article
- Deep learning-assisted analysis of biomarker changes after increase of dosing from aflibercept 2 mg to 8 mg in therapy-resistant neovascular age-related macular degeneration.BMJ open ophthalmology · 2025Article
- Deep-Learning-Assisted Analysis of Early Biomarker Changes in Treatment-Naïve Patients with Neovascular AMD Under Intravitreal Faricimab.Ophthalmology and therapy · 2025Article
- Deep learning assisted analysis of biomarker changes in refractory neovascular AMD after switch to faricimab.International journal of retina and vitreous · 2025Article
- Reconstructing disease dynamics for mechanistic insights and clinical benefit.Nature communications · 2023Article
- Application of Artificial Intelligence in Ophthalmology: An Updated Comprehensive Review.Journal of ophthalmic & vision researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectivesTo determine real-life quantitative changes in OCT biomarkers in a large set of treatment naive patients in a real-life setting undergoing anti-VEGF therapy. For this purpose, we devised a novel deep learning based semantic segmentation algorithm providing the first benchmark results for automatic segmentation of 11 OCT features including biomarkers for neovascular age-related macular degeneration (nAMD).
methodsTraining of a Deep U-net based semantic segmentation ensemble algorithm for state-of-the-art semantic segmentation performance which was used to analyze OCT features prior to, after 3 and 12 months of anti-VEGF therapy.
resultsHigh F1 scores of almost 1.0 for neurosensory retina and subretinal fluid on a separate hold-out test set with unseen patients. The algorithm performed worse for subretinal hyperreflective material and fibrovascular PED, on par with drusenoid PED, and better in segmenting fibrosis. In the evaluation of treatment naive OCT scans, significant changes occurred for intraretinal fluid (mean: 0.03 µm
conclusionsThe segmentation algorithm allows efficient volumetric analysis of OCT scans. Anti-VEGF provokes most potent changes in the first 3 months while a gradual loss of RPE hints at a progressing decline of visual acuity. Additional research is required to understand how these accurate OCT predictions can be leveraged for a personalized therapy regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.